Financial Contrast: Eleven Biotherapeutics (EBIO) vs. Its Rivals
Eleven Biotherapeutics (NASDAQ: EBIO) is one of 295 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Eleven Biotherapeutics to related companies based on the strength of its valuation, profitability, analyst recommendations, dividends, risk, institutional ownership and earnings.
This is a summary of current ratings and target prices for Eleven Biotherapeutics and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Eleven Biotherapeutics Competitors||758||3018||11153||227||2.72|
As a group, “Bio Therapeutic Drugs” companies have a potential upside of 34.93%. Given Eleven Biotherapeutics’ peers higher possible upside, analysts clearly believe Eleven Biotherapeutics has less favorable growth aspects than its peers.
Institutional & Insider Ownership
5.1% of Eleven Biotherapeutics shares are owned by institutional investors. Comparatively, 51.0% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 28.7% of Eleven Biotherapeutics shares are owned by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Eleven Biotherapeutics and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Eleven Biotherapeutics||$29.90 million||$9.65 million||5.81|
|Eleven Biotherapeutics Competitors||$260.16 million||$66.28 million||-6.75|
Eleven Biotherapeutics’ peers have higher revenue and earnings than Eleven Biotherapeutics. Eleven Biotherapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Risk and Volatility
Eleven Biotherapeutics has a beta of 3.51, suggesting that its stock price is 251% more volatile than the S&P 500. Comparatively, Eleven Biotherapeutics’ peers have a beta of 6.66, suggesting that their average stock price is 566% more volatile than the S&P 500.
This table compares Eleven Biotherapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Eleven Biotherapeutics Competitors||-11,940.42%||-482.37%||-44.32%|
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company’s therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF).
Receive News & Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.